Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$149.76 USD

149.76
1,714,060

+5.62 (3.90%)

Updated Nov 1, 2024 04:00 PM ET

Pre-Market: $150.42 +0.66 (0.44%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Illumina (ILMN) Expands NIPT Offering With New Collaboration

by Zacks Equity Research

Illumina's (ILMN) VeriSeq NIPT Solution v2 provides accurate, consistent and scalable end-to-end genome-wide noninvasive prenatal testing.

BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch

by Zacks Equity Research

BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.

Cooper Companies (COO) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.

Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis

by Zacks Equity Research

Bristol Myers (BMY) gets FDA approval for Zeposia to treat adults with moderate-to-severe active ulcerative colitis. This marks the second indication for the drug.

Change Healthcare (CHNG) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance in the Network Solutions segment.

Illumina (ILMN) Down 1.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NextGen (NXGN) Announces Positive Telehealth Survey Results

by Zacks Equity Research

NextGen's (NXGN) recent survey indicates growing preference for telehealth services.

QIAGEN (QGEN)-Mirati Deal to Boost Companion Diagnostic Arm

by Zacks Equity Research

QIAGEN's (QGEN) alliance will facilitate co-development of KRAS companion diagnostic with Mirati's, adagrasib, a selective and potent oral inhibitor of KRAS G12C.

Allscripts (MDRX), Lash Group Team Up for Better Patient Care

by Zacks Equity Research

Allscripts' (MDRX) Veradigm enters collaboration to streamline specialty medication management for medical clinics and practices across the nation.

Exact Sciences (EXAS) Reveals Promising Data on Cologuard

by Zacks Equity Research

Modeling data exhibits efficacy of Exact Sciences' (EXAS) Cologuard compared to FIT and other colorectal cancer diagnostic options.

Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Glaukos (GKOS) owing to its strategic alliances and a strong iStent product line.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI), owing to its potential in the Peripheral Intervention arm and strong international foothold.

PerkinElmer's (PKI) COVID-19 Test Kit Part of Investigative Study

by Zacks Equity Research

PerkinElmer's (PKI) test kit, which is currently being used in an investigative study, is aimed at accelerating the vaccine development and treatments against COVID-19.

Ecolab (ECL) Launches Roach Control Device for Food Outlets

by Zacks Equity Research

Ecolab's (ECL) latest device is expected to help the restaurant industry efficiently protect their brand reputation and eliminate any business and public health risk.

Here's Why You Should Hold on to Avanos (AVNS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS), owing to its strong product line and focus on its R&D.

NextGen (NXGN) Implements API to Aid COVID-19 Vaccination

by Zacks Equity Research

NextGen's (NXGN) API is expected to address the unique and evolving reporting needs of various states as they administer the COVID-19 vaccine.

The Zacks Analyst Blog Highlights: PulteGroup, Weyerhaeuser, General Motors, Illumina and Marriott International

by Zacks Equity Research

The Zacks Analyst Blog Highlights: PulteGroup, Weyerhaeuser, General Motors, Illumina and Marriott International

Nalak Das headshot

Top 5 S&P 500 Stocks at Lucrative Valuation Amid May Turmoil

by Nalak Das

We have narrowed down our search to five S&P 500 stocks that have attained a 52-week high this year but are currently trading at a deep discount. These are: MAR, PHM, WY, GM and ILMN.

STERIS (STE) Q4 Earnings Fall Shy of Estimates, FY22 View Up

by Zacks Equity Research

STERIS' (STE) fourth-quarter 2021 revenues improved year over year on robust growth across three segments.

National Vision (EYE) Q1 Earnings Top Estimates, View Up

by Zacks Equity Research

According to National Vision (EYE), increased demand for low-cost eye exams, glasses and contact lenses boosts first-quarter performance.

Haemonetics (HAE) Q4 Earnings Lag Estimates, Gross Margin Dips

by Zacks Equity Research

Haemonetics' (HAE) fourth-quarter fiscal 2021 revenues declined 5.6% year over year due to the pandemic.

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.

Cardiovascular Systems (CSII) Q3 Loss Widens, Gross Margin Dips

by Zacks Equity Research

Increase in vaccinations and simultaneous decrease in COVID-19 hospitalizations in February and March result in improved procedure volumes for Cardiovascular Systems (CSII) in Q3.